Determination of adriamycin content in pectin–adriamycin conjugate in a two-phase reaction system by high-performance liquid chromatography

• Autorzy: Ran M. , Xie P. , Tang X. , Zeng G. , Yang J.

Identyfikatory

DOI

10.1556/1326.2017.00201

• Języki publikacji: EN

Abstrakty

EN

A newly proposed method for detecting content of adriamycin in pectin–adriamycin conjugate has been developed and evaluated. The content of adriamycin was detected by selective degradation of adramycin to adriamycinone. It was realized by a two-phase reaction system (water–chloroform reaction system), in which adriamycin was quantitatively converted to adriamycinone. Therefore, the latter can be used to calculate the precise content of adramycin in the polymer drug. To develop the method, the catalyst for degradation, the extraction solvent for adriamycinone, the temperature and time of degradation, and the ratio of pectin–adriamycin conjugate were investigated. The optimal reaction condition was as follows: 30 mg of pectin–adriamycin conjugate dissolved in 25 mL of water was added to a mixture of 25 mL of hydrochloric acid (1.5 mol/L) and 50 mL of chloroform; the mixture was heated to 40 °C to react for 1.5 h; after that, the mixture was extracted with chloroform for three times, and then the organic layer was combined and, subsequently, evaporated to remove solvent. Under this condition, adriamycinone generation rate reached 99.87%. The quantitative method was evaluated for linearity, the limit of detection (LOD) and limit of quantitation (LOQ), recovery, accuracy, robustness, and precision. The recoveries were between 99.47% and 101.07% with relative standard deviation <1.23%. The LOD and LOQ were 0.06 and 0.17 μg/mL, respectively. Compared to the traditional ultraviolet (UV) detection, this method is considered to be more precise for detecting content of adriamycin in its polymer conjugate.

Słowa kluczowe

EN

Two-phase reaction system; pectin–adriamycin conjugate; high-performance liquid chromatography; adriamycinone generation rate; drug loading

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2018
• Tom: Vol. 30, no. 2
• Strony: 103--108
• Opis fizyczny: Bibliogr. 22 poz., rys.

Twórcy

autor

Ran M.

• Laboratory of Cancer Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China
• Chongqing Lummy Pharmaceutical Co., Ltd., Chongqing 401336, China

autor

Xie P.

• State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, Chengdu 610041, China

autor

Tang X.

• Chongqing Lummy Pharmaceutical Co., Ltd., Chongqing 401336, China

autor

Zeng G.

• Chongqing Lummy Pharmaceutical Co., Ltd., Chongqing 401336, China
• College of Life Sciences, Sichuan Normal University, Chengdu 610101, China

autor

Yang J.

• Laboratory of Cancer Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China

Bibliografia

• [1] Wong, B. S.; Yoong, S. L.; Jagusiak, A.; Panczyk, T.; Ho, H. K.; Ang, W. H.; Pastorin, G. Adv. Drug. Deliv. Rev. 2013, 65, 1992–1996.
• [2] Sheng, Y.; Xu, J. H.; You, Y. W.; Xu, F. F.; Chen, Y. Mol. Pharm. 2015, 12, 2217–2228.
• [3] Peng, Z. H.; Kopecek, J. J. Am. Chem. Soc. 2015, 137, 6726–6729.
• [4] Qiao, Z. Y.; Hou, C. Y.; Zhang, D.; Liu, Y.; Lin, Y. X.; An, H. W.; Li, X. J.; Wang, H. J. Mater. Chem. B. 2015, 3, 2943–2953.
• [5] Zhong, Y. J.; Shao, L. H.; Li, Y. Int. J. Oncol. 2013, 42, 373–383.
• [6] Paci, A.; Veal, G.; Bardin, C.; Leveque, D.; Widmer, N.; Beijnen, J.; Astier, A.; Chatelut, E. Eur. J. Cancer. 2014, 50, 2010–2019.
• [7] Marchetti, C.; Palaia, I.; Giorgini, M.; De Medici, C.; Ladarola, R.; Vertechy, L.; Domenici, L.; Di Donato, V.; Tomao, F.; Muzii, L.; Benedetti Panici, P. OncoTargets. Ther. 2014, 7, 1223–1236.
• [8] Oberoi, H. S.; Nukolova, N. V.; Kabanov, A. V.; Bronich, T. K. Adv. Drug. Deliv. Rev. 2013, 65, 1667–1685.
• [9] Schroeder, A.; Heller, D. A.; Winslow, M. M.; Dahlman, J. E.; Pratt, G. W.; Langer, R.; Jacks, T.; Anderson, D. G. Nat. Rev. Cancer. 2011, 12, 39–50.
• [10] Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nat. Nanotechnol. 2007, 2, 751–760.
• [11] Kwon, G. S.; Forrest, M. L. Drug. Dev. Res. 2006, 67, 15–22.
• [12] Chen, H. B.; Chiou, B. S.; Wang, Y. Z.; Schiraldi, D. A. ACS. Appl. Mater. Interfaces. 2013, 5, 1715–1721.
• [13] Moreira, H. R.; Munarin, F.; Gentilini, R.; Visai, L.; Granja, P. L.; Tanzi, M. C.; Petrini, P. Carbohydr. Polym. 2014, 103, 339–347.
• [14] Szu, S. C.; Lin, K. F.; Hunt, S.; Chu, C.; Thinh, N. D. Vaccine 2014, 32, 2618–2622.
• [15] Tang, X. H.; Xie, P.; Ding, Y.; Chu, L. Y.; Hou, J. P.; Yang, J. L.; Song, X.; Xie, Y. M. Bioorg. Med. Chem. 2010, 18, 1599–1609.
• [16] Yuan, F.; Chen, F.; Xiang, Q. Y.; Qin, X.; Zhang, Z. R.; Huang, Y. Chin. Chem. Lett. 2008, 19, 137–140.
• [17] Chen, Z.; Zhang, P.; Cheetham, A. G.; Moon, J. H.; Moxley, J. W.; Lin, Y. A.; Cui, H. J. Control. Release. 2014, 191, 123–130.
• [18] Etrych, T.; Strohalm, J.; Chytil, P.; Cernoch, P.; Starovoytova, L.; Pechar, M.; Ulbrich, K. Eur. J. Pharm. Sci 2011, 42, 527–539.
• [19] Nair, J. B.; Mohapatra, S.; Ghosh, S.; Maiti, K. K. Chem. Commun. 2015, 51, 2403–2406.
• [20] Wei, R.; Cheng, L.; Zheng, M.; Cheng, R.; Meng, F.; Deng, C.; Zhong, Z. Biomacromolecules 2012, 13, 2429–2438.
• [21] Fraier, D.; Frigerio, E.; Pianezzola, E.; Strolin Benedetti, M.; Cassidy, J.; Vasey, P. J. Pharm. Biomed. Anal. 1995, 13, 625–633.
• [22] Shiah, J. J.; Sun, Y.; Peterson, C. M.; Kopecek, J. J. Control. Release. 1999, 61, 145–157.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).